Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ DR4 Monoclonal Antibody (32A242)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA141049
Description
Suggested positive control: Hela whole cell extract, HeLa cell lysate.
TRAIL-R1 (CD261, DR4) is a type I transmembrane protein, also called TRAIL receptor 1. The ligand for this DR4 death receptor has been identified and termed TRAIL, which is a member of the TNF family. DR4, as many other receptors (Fas, TNFR1, etc.), mediates apoptosis and NF kappaB activation in many cells and tissues. Apoptosis, a programmed cell death, is a operating process in normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by coupled of certain cytokines (TNF family - TNF, Fas ligand) and their death domain containing receptors (TNFR1, Fas receptor).
Specifications
DR4 | |
Monoclonal | |
1.0 mg/mL | |
PBS with 0.05% sodium azide | |
O00220 | |
TNFRSF10A | |
Synthetic peptide corresponding to residues 2-21 of mature human DR4. | |
100 μg | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG1 |
Western Blot, Immunocytochemistry | |
32A242 | |
Unconjugated | |
TNFRSF10A | |
APO2; CD261; cytotoxic TRAIL receptor; death receptor 4; DR4; MGC9365; sCD261; soluble CD261; soluble TRAIL; sTRAIL; TNF receptor superfamily member 10a; TNF-related apoptosis-inducing ligand receptor 1; TNFRSF10A; TRAIL R1; TRAIL receptor 1; TRAILR1; TRAIL-R1; TRAILR-1; tumor necrosis factor receptor superfamily member 10A; tumor necrosis factor receptor superfamily member 10a variant 2; tumor necrosis factor receptor superfamily, member 10a | |
Mouse | |
Protein G | |
RUO | |
8797 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction